This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Analysts Name Top Biotech Stocks for 2010: BioBuzz

Either way, the search for a new Biogen CEO, which the company said is already underway, will be an interesting process to watch. Now that Mullen is essentially a lame duck, it's reasonable to expect the company's board -- including Icahn's proxies -- to take a more active management role.

Naturally, speculation will increase that Biogen could be placed back on the sale block.

It might be lost amidst all the palace intrigue, but Mullen did manage to bring home a 12% return for shareholders in 2009 -- making Biogen the only big-cap biotech stock to close the year in the green.

Still, Biogen does face challenges ahead with the increase in the number of cases of the serious brain infection known as PML tied to use of its multiple sclerosis drug Tysabri. The company has also experienced setbacks recently with its late-stage drug pipeline.

Biogen shares closed Monday at $53.64, ahead of the announcement of Mullen's retirement.

Help Wanted: Big-Cap Biotech CEO

Running a multi-billion dollar, profitable biotech firm isn't a position that comes available very often, which makes the search for a new CEO at Biogen Idec a relatively rare event.

Mullen joined Biogen in 1989 and rose to the CEO post in 2000, the same year that Amgen's (AMGN - Get Report) current CEO Kevin Sharer also took over the top job at his company.

Genzyme's (GENZ) CEO Henri Termeer is the longest-serving CEO in the big-cap biotech group, named to the position in 1985. (How long he stays there is also an intriguing question for 2010.)

John Martin became Gilead Sciences (GILD) CEO in 1996, while Celgene (CELG - Get Report) CEO Sol Barer is a relative newcomer, having been promoted to his position in 2006. (Although Barer's tenure with Celgene began in 1987.)

5 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ACOR $30.42 1.40%
AMGN $157.12 0.43%
CELG $113.31 -0.50%
INCY $108.35 0.32%
RIGL $3.71 5.10%

Markets

DOW 18,093.35 +81.41 0.45%
S&P 500 2,113.25 +3.65 0.17%
NASDAQ 5,098.2490 +21.7250 0.43%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs